amyloidosis: A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
176 |
4. Check minimum number of eventsNone |
176 |
5. Include endpointsNone |
176 |
6. Filter based on genotype QC (FinnGen only) |
172 |
Control definitions (FinnGen only)
- Control exclude
- E4_METABOLIA
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E85
- Name in latin
- Amyloidosis in uno organo
Similar endpoints
↥List of similar endpoints to
Organ-limited amyloidosis
based on the number of shared cases.
Similar with more cases:
- Amyloidosis
- Metabolic disorders
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1581 | 719 | 850 |
| Only index persons | 1221 | 545 | 676 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 83.24 | 84.01 | 82.64 |
| Only index persons | 83.19 | 84.14 | 82.43 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 172 | 61 | 111 |
| Unadjusted period prevalence (%) | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | 78.06 | 72.22 | 81.26 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 176
- Matched controls
- 1760
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E85.4
ICD-10 Finland
Organ-limited amyloidosis
+∞
254.6
176
*
E85.9
ICD-10 Finland
Amyloidosis, unspecified
+∞
50.5
46
*
I43.1*E85.9
ICD-10 Finland
Cardiac amyloidosis
+∞
36.8
34
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.7
22.1
76
245
I50.9
ICD-10 Finland
Heart failure, unspecified
4.1
18.2
71
247
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
6.7
17.3
30
52
I50.0
ICD-10 Finland
Congestive heart failure
4.8
17.0
46
120
C03DA01
ATC
spironolactone; oral
4.7
16.8
47
126
E85.89
ICD-10 Finland
Other amyloidosis
+∞
15.9
15
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.9
15.1
58
196
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.5
14.2
114
609
C03CA01
ATC
furosemide; systemic
3.4
14.0
107
554
FJA10
NOMESCO Finland
Transvenous biopsy of right ventricle
+∞
12.6
12
*
E78.00
ICD-10 Finland
Familial hypercholesterolaemia
69.7
11.8
13
*
N08.4*E85.9
ICD-10 Finland
Glomerular disorders in amyloidosis
+∞
11.6
11
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.0
11.3
37
110
I61.1
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, cortical
46.5
11.1
13
*
I43.1
ICD-10 Finland
Cardiomyopathy in metabolic diseases
+∞
10.5
10
*
WX892
NOMESCO Finland
Monitored bed care
4.6
10.4
27
67
I68.0*E85.9
ICD-10 Finland
Cerebral amyloid angiopathy
+∞
9.5
9
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
5.3
8.6
18
37
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
7.1
8.5
20
31
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.9
8.4
51
220
E85.3
ICD-10 Finland
Secondary systemic amyloidosis
+∞
8.4
8
*
I69.1
ICD-10 Finland
Sequelae of intracerebral haemorrhage
15.5
8.3
13
9
I61.0
ICD-10 Finland
Intracerebral haemorrhage in hemisphere, subcortical
12.6
8.2
14
12
I25.1
ICD-10 Finland
Atherosclerotic heart disease
2.5
7.8
67
343
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.4
7.5
76
418
AA1AD
NOMESCO Finland
CT of head and brain
2.5
7.4
66
342
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
6.1
7.3
19
34
NA1AA
NOMESCO Finland
Cervical spine X-ray examination without contrast
7.7
6.9
15
21
K90
ICPC
Stroke/cerebrovascular accident
7.7
6.9
15
21
KA3AT
NOMESCO Finland
Biopsy of kidney with ultrasound guidance
41.7
6.8
8
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
12.9
6.7
11
9
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
2.5
6.7
56
281
TFJ02
NOMESCO Finland
Muscle biopsy of heart
72.4
6.5
7
*
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
72.4
6.5
7
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
18.9
6.3
9
5
N08.4
ICD-10 Finland
Glomerular disorders in other endocrine, nutritional and metabolic diseases
+∞
6.3
6
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.6
6.2
21
63
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.9
6.2
31
119
AN1
HP
Coronary angiography
3.0
6.1
30
114
207
Kela drug reimbursment
Chronic arrhythmias
2.5
6.1
48
233
E78.01
ICD-10 Finland
Pure hypercholesterolaemia
2.9
6.0
31
121
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
51
36
19.54
58.67
6.2
2.6
35.70
240.65
mg/l
0.53
39
26
51
36
19.54
58.67
6.1
2.6
52.99
34.00
mg/l
0.73
39
27
30
46
7.66
19.43
4.5
1.6
0.64
0.77
g/l
0.10
24
40
30
55
6.37
16.35
3.1
1.6
—
—
—
0
0
91
479
2.86
10.71
7.2
3.1
5075.12
1620.52
ng/l
5.44
83
409
30
81
4.26
10.39
5.7
3.3
1.46
2.28
mmol/l
0.51
24
70
98
545
2.80
10.25
7.4
4.0
72.64
45.85
ng/l
0.99
85
407
46
172
3.27
9.87
4.1
2.1
18.54
22.80
%
0.89
38
143
27
70
4.37
9.83
1.6
2.6
1.37
1.65
g/l
0.70
21
65
111
674
2.75
9.53
13.6
5.1
1.20
1.21
mmol/l
0.44
99
559
110
680
2.65
8.87
25.4
19.2
1.36
1.45
inr
0.35
28
184
53
235
2.80
8.30
1.9
1.8
—
—
—
0
0
48
203
2.88
8.20
3.7
2.0
10.27
13.20
umol/l
1.73
43
184
27
80
3.81
8.19
6.7
2.4
156.89
88.69
ng/l
1.58
20
66
47
197
2.89
8.16
2.6
2.0
29.76
30.03
s
0.11
47
189
108
687
2.48
7.82
10.2
8.9
4.88
4.25
e9/l
1.14
100
595
94
574
2.37
7.30
7.4
3.7
32.61
34.43
g/l
1.88
87
524
32
116
3.15
7.10
5.1
3.1
2.38
2.03
mmol/l
0.25
27
96
12
11
11.60
6.91
1.9
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
18
33
5.95
6.82
4.1
2.4
0.34
0.28
u/ml
0.59
11
20
23
71
3.58
6.54
5.6
8.2
25.11
25.26
mmol/l
0.07
23
71
60
316
2.36
6.38
4.1
2.4
423.34
5781.11
umol/l
1.31
53
258
64
352
2.29
6.11
2.6
2.1
3.27
3.30
mg/l
0.03
53
305
59
315
2.31
6.03
2.0
1.8
986.90
1158.77
nmol/l
0.85
42
238
10
9
11.69
5.87
2.7
2.8
—
—
—
0
0
16
31
5.57
5.87
3.0
2.1
118.20
123.64
g/l
—
10
25
76
463
2.13
5.53
4.0
2.3
165.52
160.68
ug/l
0.07
66
413
16
43
3.99
5.50
1.4
1.2
—
—
—
0
0
8
5
16.65
5.46
1.1
1.0
—
—
—
0
0
78
482
2.11
5.45
4.8
3.1
—
—
—
0
0
24
88
3.00
5.19
1.7
1.6
—
—
—
0
0
17
50
3.66
5.17
1.9
1.6
—
—
—
0
0
14
29
5.15
4.93
2.6
1.2
0.22
0.22
g/l
0.08
14
29
14
31
4.81
4.67
2.6
1.3
1.17
1.08
g/l
0.41
14
31
9
11
8.55
4.62
1.1
1.0
—
—
—
0
0
61
367
2.01
4.41
4.9
3.0
0.71
0.51
e6/l
0.35
51
275
11
20
5.79
4.36
1.7
1.2
—
—
—
0
0
14
35
4.25
4.21
3.4
1.5
—
—
—
0
0
17
58
3.14
4.14
2.1
1.8
—
—
—
0
0
14
36
4.13
4.10
2.2
2.6
8.19
7.96
kpa
0.17
14
36
82
561
1.86
3.96
2.2
2.0
85.71
95.01
pmol/l
1.06
49
286
69
451
1.87
3.82
4.0
2.7
2.35
2.35
mmol/l
0.09
60
388
33
165
2.23
3.81
1.8
1.9
—
—
—
0
0
12
29
4.36
3.78
3.3
2.0
4.95
4.83
kpa
0.19
12
29
62
394
1.89
3.73
3.5
3.4
41.38
9.19
mg/mmol
1.87
44
239
7
9
8.04
3.59
1.1
1.0
46.43
35.67
u/l
—
7
9
13
39
3.52
3.30
2.5
2.5
24.04
25.47
mmol/l
0.65
13
39
16
61
2.79
3.23
1.9
3.1
—
—
—
0
0
31
164
2.08
3.10
1.8
1.8
—
—
—
0
0
142
1203
1.93
3.02
33.5
16.0
27.39
28.04
mg/l
0.09
129
978
8
17
4.88
2.95
1.4
1.4
—
—
—
0
0
12
288
0.37
2.90
2.2
1.6
1.22
1.25
mmol/l
0.07
12
223
73
519
1.69
2.87
2.3
2.3
—
—
—
0
0
11
35
3.28
2.70
1.8
1.1
—
—
—
0
0
22
108
2.19
2.65
2.5
1.5
—
—
—
0
0
42
261
1.80
2.62
2.0
1.6
1.91
1.47
mg/l
0.38
29
202
13
50
2.73
2.59
1.5
1.8
—
—
—
0
0
47
306
1.73
2.50
2.3
2.7
—
—
—
0
0
77
571
1.62
2.49
2.9
2.9
—
—
—
0
0
8
22
3.76
2.39
1.1
1.1
—
—
—
0
0
11
39
2.94
2.39
2.1
1.4
—
—
—
0
0
43
278
1.72
2.33
2.3
2.8
2.50
2.45
mmol/l
1.09
35
237
79
598
1.58
2.31
4.3
3.9
0.00
0.00
estimate
-0.00
25
108
7
18
4.00
2.27
1.3
1.9
—
—
—
0
0
9
29
3.21
2.26
1.6
1.5
—
—
—
0
0
87
678
1.56
2.21
3.7
2.8
56.87
52.04
u/l
0.30
82
618
24
131
1.96
2.21
5.7
3.7
—
—
—
0
0
18
88
2.16
2.20
1.4
1.4
—
—
—
0
0
145
1278
1.76
2.17
15.4
10.3
22.87
23.54
u/l
0.34
138
1215
145
1281
1.75
2.12
40.6
18.2
138.97
139.74
mmol/l
2.28
139
1234
22
120
1.95
2.04
7.7
3.5
1.20
1.22
mmol/l
0.51
22
102
9
32
2.91
2.03
1.1
1.3
—
—
—
0
0
145
1286
1.72
2.02
41.2
18.2
4.04
4.01
mmol/l
0.62
139
1238
33
206
1.74
2.02
3.9
2.8
2.24
1.76
e6/l
0.11
17
116
51
358
1.60
2.00
2.5
3.2
0.67
0.83
ug/l
0.77
38
251
28
168
1.79
1.95
1.3
1.3
47.20
45.69
iu/ml
—
8
48
147
1315
1.72
1.90
45.9
23.3
232.50
236.57
e9/l
0.30
141
1270
147
1316
1.71
1.89
47.4
23.4
38.13
39.37
%
1.36
134
1206
147
1316
1.71
1.89
45.8
23.2
4.23
4.41
e12/l
3.71
139
1258
28
174
1.72
1.74
11.0
6.7
1.27
1.42
mmol/l
0.06
23
133
5
13
3.92
1.72
1.2
1.1
—
—
—
0
0
75
592
1.47
1.68
6.0
5.2
0.00
0.00
estimate
-0.00
26
109
6
19
3.23
1.67
1.2
1.1
—
—
—
0
0
62
472
1.48
1.66
2.3
2.0
81.67
78.47
nmol/l
0.36
55
404
33
219
1.62
1.62
3.8
2.7
0.44
1.19
e6/l
2.45
16
130
75
600
1.44
1.53
4.3
3.9
0.00
0.00
estimate
-0.00
26
122
7
27
2.66
1.53
1.4
1.6
—
—
—
0
0
101
855
1.43
1.50
3.6
3.6
14.98
15.07
pmol/l
0.13
88
746
42
302
1.51
1.46
1.6
1.9
492.66
424.06
pmol/l
0.73
35
241
6
22
2.79
1.44
1.8
1.5
—
—
—
0
0
128
1136
1.46
1.44
5.4
6.0
41.84
40.57
mmol/mol
0.79
113
1027
6
23
2.66
1.38
5.5
3.3
58.67
60.04
%
—
6
23
132
1186
1.45
1.32
4.8
5.0
5.88
6.06
mmol/l
1.11
119
1039
6
24
2.55
1.31
1.2
1.6
—
—
—
0
0
5
18
2.83
1.29
2.6
4.2
—
—
—
0
0
132
1190
1.44
1.26
4.8
5.1
2.40
2.61
mmol/l
2.29
117
1042
62
495
1.39
1.24
3.6
4.9
20.57
21.32
%
0.17
32
260
24
160
1.58
1.17
1.3
1.3
4.00
12.95
u/ml
—
10
57
122
1094
1.38
1.14
4.6
4.3
2.34
2.04
mu/l
1.32
106
955
15
89
1.75
1.11
18.5
9.2
94.29
93.64
%
0.25
15
89
123
1107
1.37
1.10
4.3
4.1
1.24
1.24
mmol/l
0.03
109
968
7
32
2.24
1.09
1.4
1.3
—
—
—
0
0
7
32
2.24
1.09
1.4
1.3
—
—
—
0
0
45
348
1.39
1.07
1.7
1.6
24.18
21.15
nmol/l
0.47
38
294
6
27
2.26
0.94
2.0
1.3
—
—
—
0
0
72
610
1.31
0.94
4.7
5.6
3.65
5.20
ug/l
0.38
64
523
6
29
2.11
0.90
1.2
1.5
—
—
—
0
0
43
343
1.34
0.85
4.5
4.2
0.05
0.00
estimate
0.48
19
104
6
33
1.85
0.80
1.2
1.5
—
—
—
0
0
125
1153
1.29
0.78
4.7
4.5
4.25
4.50
mmol/l
1.77
113
1029
7
38
1.88
0.74
1.4
1.6
—
—
—
0
0
11
68
1.66
0.73
3.6
1.9
1.84
1.67
%
0.32
11
50
7
39
1.83
0.73
1.4
1.5
—
—
—
0
0
20
144
1.44
0.72
14.6
7.4
121.70
122.00
g/l
0.02
20
139
5
27
1.88
0.69
1.2
1.5
—
—
—
0
0
23
172
1.39
0.68
15.1
8.1
—
—
—
0
0
23
172
1.39
0.68
15.3
5.8
103.17
104.30
mmol/l
0.59
23
172
123
1144
1.25
0.65
4.7
4.5
1.39
1.46
mmol/l
0.82
110
1006
122
1136
1.24
0.63
32.5
14.6
65.00
72.86
ml/min/173m2
2.75
103
940
25
197
1.31
0.55
1.2
1.2
0.97
3.00
u/ml
—
6
47
23
179
1.33
0.55
3.3
4.6
34.50
32.39
%
0.46
16
114
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
5
34
1.48
0.40
3.2
1.2
34550.00
10035.52
e6/l
—
5
21
53
477
1.16
0.35
4.8
4.2
—
—
—
0
0
14
109
1.31
0.34
1.1
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
8
72
1.12
0.16
3.4
2.2
1.13
1.10
%
—
8
72
8
91
0.87
0.07
2.0
1.3
—
—
—
0
0
10
107
0.93
0.02
5.3
6.2
23.74
24.47
mmol/l
—
10
99
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_AMYL_ORGAN and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_AMYL_ORGAN.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_AMYL_ORGAN – Organ-limited amyloidosis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data